

Corine H Geurts Van Kessel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6070101/publications.pdf>

Version: 2024-02-01

66
papers

6,931
citations

218381

26
h-index

98622

67
g-index

84
all docs

84
docs citations

84
times ranked

14487
citing authors

#	ARTICLE	IF	CITATIONS
1	Durability of Immune Responses After Boosting in Ad26.COVID-19-S-Primed Healthcare Workers. <i>Clinical Infectious Diseases</i> , 2023, 76, e533-e536.	2.9	7
2	Antibody and T-Cell Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. <i>Clinical Infectious Diseases</i> , 2023, 76, e188-e199.	2.9	24
3	Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell-Depleted Patients. <i>Clinical Infectious Diseases</i> , 2022, 74, 1271-1274.	2.9	19
4	Persistent Health Problems beyond Pulmonary Recovery up to 6 Months after Hospitalization for COVID-19: A Longitudinal Study of Respiratory, Physical, and Psychological Outcomes. <i>Annals of the American Thoracic Society</i> , 2022, 19, 551-561.	1.5	33
5	Understanding the association between sleep, shift work and COVID-19 vaccine immune response efficacy: Protocol of the S-CORE study. <i>Journal of Sleep Research</i> , 2022, 31, e13496.	1.7	14
6	Interferon- γ Auto-antibodies in Convalescent Plasma Therapy for COVID-19. <i>Journal of Clinical Immunology</i> , 2022, 42, 232-239.	2.0	26
7	Experimental and field investigations of exposure, replication and transmission of SARS-CoV-2 in pigs in the Netherlands. <i>Emerging Microbes and Infections</i> , 2022, 11, 91-94.	3.0	11
8	The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. <i>Transplantation</i> , 2022, 106, 821-834.	0.5	127
9	High antibody response in relation to immunosuppressive blood levels in liver transplant recipients after SARS-CoV-2 vaccination: an observational, cohort study. <i>Gut</i> , 2022, 71, 2605-2608.	6.1	3
10	Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COVID-19-S Priming. <i>New England Journal of Medicine</i> , 2022, 386, 951-963.	13.9	102
11	Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. <i>Science Immunology</i> , 2022, 7, eabo2202.	5.6	337
12	From more testing to smart testing: data-guided SARS-CoV-2 testing choices, the Netherlands, May to September 2020. <i>Eurosurveillance</i> , 2022, 27, .	3.9	9
13	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 385-401.	12.5	135
14	Poxvirus MVA Expressing SARS-CoV-2 S Protein Induces Robust Immunity and Protects Rhesus Macaques From SARS-CoV-2. <i>Frontiers in Immunology</i> , 2022, 13, 845887.	2.2	13
15	High torque tenovirus (TTV) load before first vaccine dose is associated with poor serological response to COVID-19 vaccination in lung transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 765-772.	0.3	15
16	Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?. <i>Vaccine</i> , 2022, 40, 2251-2257.	1.7	32
17	Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1949-1957.	1.5	39
18	Ongoing rabies outbreak in dogs of unprecedented scale and human cases in Nelson Mandela Bay Municipality, South Africa, up to 13 February 2022. <i>Eurosurveillance</i> , 2022, 27, .	3.9	2

#	ARTICLE	IF	CITATIONS
19	Immunogenicity after second and third mRNA-1273 vaccination doses in patients receiving chemotherapy, immunotherapy, or both for solid tumours. <i>Lancet Oncology</i> , The, 2022, 23, 833-835.	5.1	18
20	Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients. <i>Nature Communications</i> , 2022, 13, 2583.	5.8	25
21	Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct. <i>Science Immunology</i> , 2022, 7, .	5.6	89
22	Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern. <i>MBio</i> , 2022, 13, .	1.8	9
23	Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters. <i>Emerging Microbes and Infections</i> , 2022, 11, 1778-1786.	3.0	7
24	Reinfection of Severe Acute Respiratory Syndrome Coronavirus 2 in an Immunocompromised Patient: A Case Report. <i>Clinical Infectious Diseases</i> , 2021, 73, e2841-e2842.	2.9	77
25	Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. <i>Science</i> , 2021, 371, 172-177.	6.0	878
26	COVID-19 vaccination: the VOICE for patients with cancer. <i>Nature Medicine</i> , 2021, 27, 568-569.	15.2	53
27	Street RABV Induces the Cholinergic Anti-inflammatory Pathway in Human Monocyte-Derived Macrophages by Binding to nAChR $\alpha 7$. <i>Frontiers in Immunology</i> , 2021, 12, 622516.	2.2	12
28	Guillain-Barré Syndrome in Suriname; Clinical Presentation and Identification of Preceding Infections. <i>Frontiers in Neurology</i> , 2021, 12, 635753.	1.1	4
29	Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. <i>Nature Communications</i> , 2021, 12, 3189.	5.8	139
30	Clinical Evaluation of Roche SD Biosensor Rapid Antigen Test for SARS-CoV-2 in Municipal Health Service Testing Site, the Netherlands. <i>Emerging Infectious Diseases</i> , 2021, 27, 1323-1329.	2.0	78
31	SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. <i>Science Immunology</i> , 2021, 6, .	5.6	455
32	Temporal Kinetics of RNAemia and Associated Systemic Cytokines in Hospitalized COVID-19 Patients. <i>MSphere</i> , 2021, 6, e0031121.	1.3	15
33	SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model. <i>Journal of Infectious Diseases</i> , 2021, 223, 2020-2028.	1.9	28
34	Diagnostic accuracy of rapid antigen tests in asymptomatic and presymptomatic close contacts of individuals with confirmed SARS-CoV-2 infection: cross sectional study. <i>BMJ</i> , The, 2021, 374, n1676.	3.0	73
35	A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection. <i>Nature Communications</i> , 2021, 12, 4635.	5.8	72
36	Heterologous Ad26.COVS Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol. <i>Frontiers in Immunology</i> , 2021, 12, 753319.	2.2	13

#	ARTICLE	IF	CITATIONS
37	The role of antibody indexes in clinical virology. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1207-1211.	2.8	17
38	Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test. <i>One Health</i> , 2021, 13, 100313.	1.5	28
39	Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). <i>Nature Communications</i> , 2021, 12, 267.	5.8	601
40	Uncovering a conserved vulnerability site in SARS-CoV-2 by a human antibody. <i>EMBO Molecular Medicine</i> , 2021, 13, e14544.	3.3	17
41	Measles seroprevalence among Dutch travelling families. <i>Travel Medicine and Infectious Disease</i> , 2021, 44, 102194.	1.5	2
42	mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. <i>Lancet Oncology</i> , The, 2021, 22, 1681-1691.	5.1	118
43	Clinical evaluation of the SD Biosensor SARS-CoV-2 saliva antigen rapid test with symptomatic and asymptomatic, non-hospitalized patients. <i>PLoS ONE</i> , 2021, 16, e0260894.	1.1	21
44	Dried blood spot cards: A reliable sampling method to detect human antibodies against rabies virus. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008784.	1.3	6
45	Rapid SARS-CoV-2 whole-genome sequencing and analysis for informed public health decision-making in the Netherlands. <i>Nature Medicine</i> , 2020, 26, 1405-1410.	15.2	273
46	Sewage surveillance system using urological wastewater: Key to COVID-19 monitoring?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, , .	0.8	3
47	SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence. <i>Journal of Infectious Diseases</i> , 2020, 222, 1452-1461.	1.9	116
48	First molecular analysis of rabies virus in Qatar and clinical cases imported into Qatar, a case report. <i>International Journal of Infectious Diseases</i> , 2020, 96, 323-326.	1.5	8
49	Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients. <i>Emerging Infectious Diseases</i> , 2020, 26, 1478-1488.	2.0	1,389
50	An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment. <i>Nature Communications</i> , 2020, 11, 3436.	5.8	321
51	Serologic Detection of Middle East Respiratory Syndrome Coronavirus Functional Antibodies. <i>Emerging Infectious Diseases</i> , 2020, 26, 1024-1027.	2.0	16
52	An evaluation of serological methods to diagnose tick-borne encephalitis from serum and cerebrospinal fluid. <i>Journal of Clinical Virology</i> , 2019, 120, 78-83.	1.6	26
53	Diagnostic and analytical performance of the hepatitis B core related antigen immunoassay in hepatitis B patients. <i>Journal of Clinical Virology</i> , 2019, 114, 1-5.	1.6	13
54	Adherence to hepatitis A travel health guidelines: A cross-sectional seroprevalence study in Dutch travelling families - The Dutch travel Vaccination Study (DiVeST). <i>Travel Medicine and Infectious Disease</i> , 2019, 32, 101511.	1.5	3

#	ARTICLE	IF	CITATIONS
55	Guillain-Barré syndrome following varicella-zoster virus infection. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2018, 37, 511-518.	1.3	36
56	An analysis of the predictive value of the HIV Ag/Ab screening assay within the performance characteristics of the DiaSorin LIAISON XL for the detection of blood-borne viruses. <i>Journal of Clinical Virology</i> , 2018, 102, 95-100.	1.6	6
57	The performance of the Alere HIV combo point-of-care test on stored serum samples; useful for detection of early HIV-1 infections?. <i>Sexually Transmitted Infections</i> , 2018, 94, 331-333.	0.8	12
58	Re-evaluation of routine dengue virus serology in travelers in the era of Zika virus emergence. <i>Journal of Clinical Virology</i> , 2017, 92, 25-31.	1.6	56
59	Hyperferritinemia is a potential marker of chronic chikungunya: A retrospective study on the Island of Curaçao during the 2014–2015 outbreak. <i>Journal of Clinical Virology</i> , 2017, 86, 31-38.	1.6	22
60	Yellow fever in a traveller returning from Suriname to the Netherlands, March 2017. <i>Eurosurveillance</i> , 2017, 22, .	3.9	17
61	Zika Virus Infection and Guillain-Barré Syndrome in Three Patients from Suriname. <i>Frontiers in Neurology</i> , 2016, 7, 233.	1.1	17
62	Acute influenza virus-associated encephalitis and encephalopathy in adults: a challenging diagnosis. <i>JMM Case Reports</i> , 2016, 3, e005076.	1.3	45
63	Miscarriage Associated with Zika Virus Infection. <i>New England Journal of Medicine</i> , 2016, 375, 1002-1004.	13.9	142
64	Challenges in laboratory diagnosis of acute viral central nervous system infections in the era of emerging infectious diseases: the syndromic approach. <i>Expert Review of Anti-Infective Therapy</i> , 2016, 14, 829-836.	2.0	11
65	Two clinical cases of renal syndrome caused by Dobrava/Saaremaa hantaviruses imported to the Netherlands from Poland and Belarus, 2012–2014. <i>Infection Ecology and Epidemiology</i> , 2016, 6, 30548.	0.5	5
66	Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice. <i>Journal of Experimental Medicine</i> , 2009, 206, 2339-2349.	4.2	311